A5004094193- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Pharmaceutical industry and healthcare
- Pharmaceutical Practices and Patient Outcomes
- Biosimilars and Bioanalytical Methods
- Medication Adherence and Compliance
- Intellectual Property and Patents
- Economic and Financial Impacts of Cancer
- Biotechnology and Related Fields
- Statistical Methods in Clinical Trials
- Biomedical Ethics and Regulation
- Electronic Health Records Systems
- Pain Management and Opioid Use
- Diabetes Management and Research
- Pharmacology and Obesity Treatment
- Spondyloarthritis Studies and Treatments
- Medical Research and Practices
- Advanced Radiotherapy Techniques
- Antiplatelet Therapy and Cardiovascular Diseases
- Healthcare Systems and Technology
- Social Policy and Reform Studies
- Pharmacogenetics and Drug Metabolism
- Innovation Policy and R&D
- Pharmaceutical Quality and Counterfeiting
European Organisation for Rare Diseases
2023
University of Vienna
2014-2017
Cambridge University Press
2014-2016
Finnish Institute for Health and Welfare
2014-2016
New York University Press
2014-2016
Vienna University of Economics and Business
2014
Bien-Air Medical Technologies (Switzerland)
2014
National Health Service
2014
Bridge University
2014
University of Cambridge
2014
Drug shortages have been identified as a public health problem in an increasing number of countries. This can negatively impact on the quality and efficiency patient care, well contribute to increases cost treatment workload care providers. Shortages also raise ethical political issues. The scientific evidence drug is still scarce, but many lessons be drawn from cross-country analyses. objective this study was characterize, compare, evaluate current systemic measures legislative...
There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there safety and/or budget concerns. Dabigatran, a oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst effective treatments needed, issues elderly dabigatran due variable drug concentrations, no known antidote dependence on renal elimination. Published studies have shown be cost-effective but...
Challenges commonly encountered in HTA of orphan medicinal products (OMPs) were identified Advance-HTA. Since then, new initiatives have been developed to specifically address issues related OMPs.This study aimed understand why these England, Scotland and at European-level established whether they resolve the challenges OMPs. The work Advance-HTA was updated with a literature review conceptual framework clinical, regulatory economic for OMPs developed. programmes critiqued against...
Funding of orphan medicinal products (OMPs) is an increasing challenge in the European Union (EU).To identify different methods for public funding OMPs order to map availability rare disease patients, as well compare expenditures on 8 EU member states.Information reimbursement status 83 was collected countries by distinguishing standard and special reimbursements. In two consecutive years, total were calculated using annual EUR exchange rates. Annual per capita, a proportion GDP,...
Pharmaceutical expenditure continued to rise steadily in Austria during the 1990s and early 2000s despite a variety of reforms. However, recent reforms initiatives have moderated growth rate. These include transparent pricing new drugs generics, greater restrictions on prescribing voluntary price reductions. Alongside this, there also been enhance rational efficient prescribing. The lack published data makes it difficult fully analyze impact individual In addition, some only recently...
There is an urgent need for health authorities across Europe to fully realize potential savings from increased use of generics sustain their healthcare systems. A variety strategies were used following the availability generic losartan, first angiotensin receptor blocker (ARB) be approved and marketed, enhance its prescribing vs. single-sourced drugs in class. Demand-side ranged 100% co-payment ARBs Denmark no specific measures. We hypothesized this heterogeneity approaches would provide...
Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways patients (MAPPs). Firstly, the scope necessity MAPPs need further scrutiny, especially with regard definition unmet need. Conditional approval pathways already exist for medicines seriously debilitating or life-threatening diseases only limited number innovative. will result initially evidence about their effectiveness...
Introduction: In January 2018 the European Commission published a Proposal for Regulation on Health Technology Assessment (HTA): 'Proposal health technology assessment and amending Directive 2011/24/EU'. A number of stakeholders, including some Member States, welcomed this initiative as it was considered to improve collaboration, reduce duplication efficiency. There were however concerns its legal basis, establishment single managing authority, preservation national jurisdiction over HTA...
Aim: To assess the impact of a plethora reforms and initiatives introduced in Austria since 2002 on actual utilization expenditure proton pump inhibitors statins. Methods: Utilization dispensed prescriptions ambulatory care was captured from 2001 to 2007 using defined daily doses (DDD) as well DDDs/1000 inhabitants/day for patients covered by social health insurance system. The data were provided internal warehouse Hauptverband der Österreichischen Sozialversicherungsträger. Total costs...
Generic atypical antipsychotic drugs offer health authorities opportunities for considerable savings. However, schizophrenia and bipolar disorders are complex diseases that require tailored treatments. Consequently, generally there have been limited demand-side measures by to encourage the preferential prescribing of generics. This is unlike situation with hypertension, hypercholaesterolaemia or acid-related stomach disorders. The objectives this study were compare effect in Western European...
Generic medications offer substantial potential cost savings to health systems compared their branded counterparts. In Europe and the US, they are only approved if bioequivalent respective originator product. Nevertheless, lack of clinical outcomes is sometimes used as reason for hesitancy in prescribing generics. We performed an observational retrospective study on 17 vs. generic pharmaceutical substances treatment hypertension/heart failure, hyperlipidemia, diabetes mellitus a dataset...
Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease diagnosed prevalence of 2.0%. Fortunately, it now curable in most patients. Sales medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by launch protease inhibitors (PIs) boceprevir (BCV) telaprevir (TVR) addition ribavirin pegylated interferon (pegIFN). Costs will continue rise new treatments including sofosbuvir, which include free regimens. Objective: Assess uptake...
To assess the utilization of renin-angiotensin drugs, including combinations, in Austria practice given limited availability diuretics, as well impact recent reforms and initiatives on expenditure angiotensin-converting enzyme inhibitors (ACEis) angiotensin receptor blockers (ARBs), following prescribing restrictions ARBs immediately after their introduction.Utilization dispensed prescriptions ambulatory care was captured from 2001 to 2007 using defined daily doses doses/1000 inhabitants/day...
Prescribing medicines safely and effectively represents one of the greatest challenges for healthcare systems. errors are common. A recent prospective observational study in UK suggested that 10% hospital prescriptions contained senior doctors were almost as frequently culpable those who had recently graduated [1]. Avoidable adverse drug reactions a frequent cause consultations primary care, admission to increased length stay [2, 3]. All providers should be striving provide high-quality...